Drugs / Mefenamic acid
Mefenamic acid
also known as
Acide mefenamique · Acido mefenamico · CI-473 · CN-35355 · Contraflam · Dysman-250 · Dysman-500 · Gardan · +19 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PONSTEL | — | 1967-03-28 | fda.gov ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03383133 | Jan 2018 → Feb 2023 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06277609 | Feb → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05064449 | Oct → Nov 2021 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT04902105 | May → Jul 2021 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03070678 | Mar → Apr 2017 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03323671 | Aug → Dec 2017 | primary dysmenorrhea | Hanan Nabil | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT01295294 | Mar → Dec 2011 | uterine disorder | Bayer | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT01060696 | Jan 2009 → Mar 2010 | female infertility | Mahidol University | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT02183025 Comparator | Jan 1998 → Apr 1999 | primary dysmenorrhea | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/3 | NCT01942122 Comparator | Oct 2015 → Feb 2021 | ovarian endometriosis | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT02943655 Comparator | Nov 2017 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT07466342 Background | Jul 2025 → Jan 2026 | primary dysmenorrhea | Nishtar Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01598012 Background | Dec 2011 → Jul 2013 | primary dysmenorrhea | Mahidol University | Completed | No outcome recorded |
| — | NCT06369012 Comparator | Mar → Sep 2024 | uterine anomalies | Egymedicalpedia | Completed | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mefenamic acid | “a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g)” NCT03383133 ↗ |
| Known as | Acide mefenamique | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Acido mefenamico | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | CI-473 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | CN-35355 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Contraflam | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Dysman-250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Dysman-500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Gardan | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | INF-3355 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | J2.344B | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | M01AG01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | MEF | “mefenamic acid (MEF, 0.75 g)” NCT03383133 ↗ |
| Known as | Mefenamate | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Mefenaminic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Meflam 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Meflam 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Mendys | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Mephenamic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Mephenaminic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | NSC-94437 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Opustan 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Opustan 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Ponstan | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Ponstan (Mefenamic acid) | “Ponstan (Mefenamic acid)” NCT01060696 ↗ |
| Known as | ponstan forte | “mefenamic acid (ponstan forte)” NCT02943655 ↗ |
| Known as | Ponstan fte | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Known as | Ponstel | ChEMBL registry synonym — accepted as the source's own label CHEMBL686 ↗ |
| Action | Inhibit | “MEF inhibits SULT with high affinity (Ki = 23 nM)” NCT03383133 ↗ |
| Modality | Small molecule | — CHEMBL686 ↗ |
| Route | Oral | “single oral use 30 minutes before SIS” NCT01060696 ↗ |